<SEC-DOCUMENT>0001213900-21-056752.txt : 20230119
<SEC-HEADER>0001213900-21-056752.hdr.sgml : 20230119
<ACCEPTANCE-DATETIME>20211104161308
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001213900-21-056752
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			China Jo-Jo Drugstores Holdings, Inc.
		CENTRAL INDEX KEY:			0001856084
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		HAI WAI HAI TONGXIN MANSION FLOOR 6
		STREET 2:		GONG SHU DISTRICT
		CITY:			HANGZHOU CITY
		STATE:			F4
		ZIP:			310008
		BUSINESS PHONE:		8657188219579

	MAIL ADDRESS:	
		STREET 1:		HAI WAI HAI TONGXIN MANSION FLOOR 6
		STREET 2:		GONG SHU DISTRICT
		CITY:			HANGZHOU CITY
		STATE:			F4
		ZIP:			310008
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>VIA EDGAR TRANSMISSION</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stacey Peikin</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lilyanna Peyser<BR>
Securities and Exchange Commission<BR>
Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Trade &amp; Services<BR>
100 F Street NE<BR>
Washington, D.C. 20549-3561</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">November 4, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 29px"><FONT STYLE="font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>China Jo-Jo Drugstores, Inc. </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Registration Statement on Form F-3 </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Filed September 21, 2021</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>File No. 333-259692</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Ms. Peikin and Ms. Peyser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter is being furnished
in response to the comment of the staff (the &ldquo;<U>Staff</U>&rdquo;) of the Division of Corporation Finance of the Securities and
Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) that was contained in the Staff&rsquo;s letter dated October 14, 2021 (the &ldquo;<U>Comment
Letter</U>&rdquo;), to China Jo-Jo Drugstores, Inc. (the &ldquo;<U>Company</U>&rdquo;) with respect to the Registration Statement on Form
F-3 filed with the Commission on September 21, 2021 (File No. 333-259692).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are the Company&rsquo;s
responses to the Staff communicated in its Comment Letter addressed to the Company. In connection with such responses, we are filing,
electronically via EDGAR, Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;F-3 (the &ldquo;<U>Registration Statement</U>&rdquo;)
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For ease of reference, each
of the Staff&rsquo;s comments is reproduced below in bold and is followed by the Company&rsquo;s responses. In addition, unless otherwise
indicated, all references to page&nbsp;numbers in such responses are to page&nbsp;numbers in the Registration Statement. Capitalized terms
used in this letter but not otherwise defined herein shall have the meaning ascribed to such term in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Registration Statement on Form F-3<BR>
Prospectus Cover Page, page i</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.45in"><B>1.</B></TD><TD STYLE="text-align: justify"><B>We note your current disclosure on the prospectus cover page. Please revise to disclose prominently
on the prospectus cover page that you are not a Chinese operating company but a Cayman Islands holding company with operations conducted
by your subsidiaries and through contractual arrangements with a variable interest entity (VIE) based in China and that this structure
involves unique risks to investors. Explain whether the VIE structure is used to replicate foreign investment in Chinese-based companies
where Chinese law prohibits direct foreign investment in the operating companies, and disclose that investors may never directly hold
equity interests in the Chinese operating company.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>We have revised the
prospectus cover page of the Registration Statement to address the Staff&rsquo;s comments mentioned above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Provide prominent disclosure about the legal and operational risks associated with being based in or
having the majority of the company&rsquo;s operations in China. Your disclosure should make clear whether these risks could result in
a material change in your operations and/or the value of the securities being offered or could significantly limit or completely hinder
your ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or
be worthless. Your disclosure should address how recent statements and regulatory actions by China&rsquo;s government, such as those related
to the use of variable interest entities and data security or anti-monopoly concerns, has or may impact the company&rsquo;s ability to
conduct its business, accept foreign investments, or list on an U.S. or other foreign exchange. Your prospectus summary should address,
but not necessarily be limited to, the risks highlighted on the prospectus cover page.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>We have revised the
prospectus cover page and the prospectus summary of the Registration Statement to address the Staff&rsquo;s comments mentioned above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD STYLE="text-align: justify"><B>Clearly disclose how you will refer to the holding company, subsidiaries, and VIEs when providing the
disclosure throughout the document so that it is clear to investors which entity the disclosure is referencing and which subsidiaries
or entities are conducting the business operations. Refrain from using terms such as &ldquo;we&rdquo; or &ldquo;our&rdquo; when describing
activities or functions of a VIE. Disclose clearly the entity (including the domicile) in which investors are purchasing their interest.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, we have revised the Registration Statement to distinguish which subsidiaries or entities are conducting the business
operations and disclosed clearly that it is the Cayman Islands holding entity in which investors are purchasing their interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Prospectus Summary, page 1 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD STYLE="text-align: justify"><B>Disclose clearly that the company uses a structure that involves a VIE based in China and what that
entails. Revise the diagram of the company&rsquo;s corporate structure on page 4 to clarify all of the equity ownership interests of each
entity, including the interests that are not held by you in Kahamadi Bio and Linjia Medical, as well as the ownership relationship between
the entities outside and inside Mainland China. Describe all contracts and arrangements through which you purport to obtain economic rights
and exercise control that results in consolidation of the VIE&rsquo;s operations and financial results into your financial statements.
Describe the relevant contractual agreements between the entities and how this type of corporate structure may affect investors and the
value of their investment, including how and why the contractual arrangements may be less effective than direct ownership and that the
company may incur substantial costs to enforce the terms of the arrangements. Disclose the uncertainties regarding the status of the rights
of the Cayman Islands holding company with respect to its contractual arrangements with the VIE, its founders and owners, and the challenges
the company may face enforcing these contractual agreements due to uncertainties under Chinese law and jurisdictional limits.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comments, we have disclosed clearly in the prospectus summary of the Registration Statement that the Company uses a structure
that involves a VIE based in China and what that entails. We have revised the Company&rsquo;s corporate structure on page 4. In addition,
we have incorporated certain information in the Registration Statement from the Annual Report on Form 10-K of our predecessor China Jo-Jo
Drugstores, Inc. (&ldquo;Predecessor CJJD&rdquo;) for the fiscal year ended March 31, 2021, filed with the Commission on June 29, 2021
(the &ldquo;2021 Annual Report&rdquo;), which further incorporated certain information from the Annual Report on Form 10-K of Predecessor
CJJD for the fiscal year ended March 31, 2020, filed with the Commission on July 10, 2020 (the &ldquo;2020 Annual Report&rdquo;). This
VIE agreements were described under &ldquo;<I>Our Corporate History and Structure</I> - <I>Contractual Arrangements with HJ Group and
the Key Personnel.&rdquo;</I> on page 4 of the 2020 Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.</B></TD><TD STYLE="text-align: justify"><B>Revise your disclosure to include a summary of risk factors, and disclose the risks that your corporate
structure and being based in or having the majority of the company&rsquo;s operations in China poses to investors. In particular, describe
the significant regulatory, liquidity, and enforcement risks with cross-references to the more detailed discussion of these risks in the
prospectus. For example, specifically discuss risks arising from the legal system in China, including risks and uncertainties regarding
the enforcement of laws and that rules and regulations in China can change quickly with little advance notice; and the risk that the Chinese
government may intervene or influence your operations at any time, or may exert more control over offerings conducted overseas and/or
foreign investment in China-based issuers, which could result in a material change in your operations and/or the value of the securities
being offered. Acknowledge any risks that any actions by the Chinese government to exert more oversight and control over offerings that
are conducted overseas and/or foreign investment in China-based issuers could significantly limit or completely hinder your ability to
offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, we have revised to include additional disclosures in the risk factor on page 11 of the Registration Statement titled
&ldquo;<I>Substantial uncertainties and restrictions with respect to the political and economic policies of the PRC government and PRC
laws and regulations could have a significant impact upon the business that we may be able to conduct in the PRC and accordingly on the
results of our operations and financial condition</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Disclose each permission that you, your subsidiaries or your VIEs are required to obtain from Chinese
authorities to operate and issue these securities to foreign investors. State whether you, your subsidiaries, or VIEs are covered by permissions
requirements from the CSRC, CAC or any other entity that is required to approve of the VIE&rsquo;s operations, and state affirmatively
whether you have received all requisite permissions and whether any permissions have been denied.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, we have incorporated certain information in the Registration Statement from the 2021 Annual Report, which further
incorporated certain information from the 2020 Annual Report. This Comment No. 6 was partially addressed under &ldquo;<I>Relevant PRC
Regulations - General PRC Government Approval &amp; Distribution of Pharmaceutical Products</I>&rdquo; on page 12 of the 2020 Annual Report.
We have further addressed this Comment No. 6 in the Registration Statement on page 8 under the heading &ldquo;<I>Licenses and Permits</I>&rdquo;,
which states that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;As a wholesale distributor and
retailer of pharmaceutical products, we are subject to regulation and oversight by different levels of the food and drug administration
in China, in particular, the National Medical Products Administration (the &ldquo;NMPA&rdquo;)&nbsp;. The&nbsp;<I>Drug Administration
Law of the PRC</I>, as amended, provides the basic legal framework for the administration of the production and sale of pharmaceutical
products in China and governs the manufacturing, distributing, packaging, pricing, and advertising of pharmaceutical products in China.
The corresponding implementation regulations set out detailed rules with respect to the administration of pharmaceuticals in China. We
are also subject to other PRC laws and regulations that are applicable to business operators, retailers, and foreign-invested companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In addition, a distributor of pharmaceutical
products must obtain a distribution permit from the relevant provincial or designated municipal-level NMPA. The grant of such permit is
subject to an inspection of the distributor&rsquo;s facilities, warehouses, hygienic environment, quality control systems, personnel,
and equipment. The distribution permit is valid for five (5) years, and the holder must apply for renewal of the permit within six (6)
months prior to its expiration. In addition, a pharmaceutical product distributor needs to obtain a business license from the relevant
administration for industry and commerce prior to commencing its business. All of our operating entities that engage in the retail pharmaceutical
business have obtained necessary pharmaceutical distribution permits, and we do not expect to face any difficulties in renewing these
permits and/or certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In addition, our operations are subject
to and affected by PRC laws and regulations. The primary governmental regulation regulating the Internet security equipment industry in
the PRC is the Cybersecurity Law, which governs entities providing &ldquo;critical information infrastructure.&rdquo; This statute provides
basic protections for Internet users, such as not selling individual&rsquo;s data to other companies without the user&rsquo;s permission
and not knowingly distributing malware. This law has become effective since June 1, 2017. Our wholly owned subsidiaries and our VIEs and
their subsidiaries are required to have, and each has, a business license issued by the PRC State Administration for Market Regulation
and its local counterparts. In addition, major PRC regulations applicable to our products and services and the Internet security industry
include Computer Information System Security Specific Product Testing and Sales License Management Method (Ministry of Public Security
Order No. 32) (&ldquo;Order 32&rdquo;) and Internet Security Protection Technology Measures Provision (Ministry of Public Security Order
No. 82) (&ldquo;Order 82&rdquo;). Order 32 sets forth the license requirement for Internet security products providers and related approval
procedures of license applications. Order 82 specifies certain security measures Internet service providers shall take to ensure Internet
security. Providers of ISP connecting service and Internet-based data processing service are within the scope of Order 82.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Regulations on Mergers and Acquisitions
of Domestic Companies by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies in 2006 and amended in 2009,
requires an overseas special purpose vehicle formed for listing purposes through acquisitions of PRC domestic companies and controlled
by PRC companies or individuals to obtain the approval of the China Securities Regulatory Commission, or CSRC prior to the listing and
trading of such special purpose vehicle&rsquo;s securities on an overseas stock exchange. Substantial uncertainty remains regarding the
scope and applicability of the M&amp;A Rules to offshore special purpose vehicles. Although we believe that CSRC&rsquo;s approval is not
required for the listing and trading of our ordinary shares on Nasdaq, we cannot assure you that relevant PRC governmental agencies, including
the CSRC, would reach the same conclusion as we do.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>7.</B></TD><TD STYLE="text-align: justify"><B>Provide a clear description of how cash is transferred through your organization. Disclose your intentions
to distribute earnings or settle amounts owed under the VIE agreements. Quantify any cash flows and transfers of other assets by type
that have occurred between the holding company, its subsidiaries, and consolidated VIEs, and direction of transfer. Quantify any dividends
or distributions that a subsidiary or consolidated VIE have made to the holding company and which entity made such transfer, and their
tax consequences. Similarly quantify dividends or distributions made to U.S. investors, the source, and their tax consequences. Describe
any restrictions on foreign exchange and your ability to transfer cash between entities, across borders, and to U.S. investors. Describe
any restrictions and limitations on your ability to distribute earnings from your businesses, including subsidiaries and/or consolidated
VIEs, to the parent company and U.S. investors as well as the ability to settle amounts owed under the VIE agreements.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, we have added a section named <I>Cash Transfer and Dividend Payment </I>under the prospectus summary on page 6
of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>8.</B></TD><TD STYLE="text-align: justify"><B>Disclose that trading in your securities may be prohibited under the Holding Foreign Companies Accountable
Act if the PCAOB determines that it cannot inspect or fully investigate your auditor, and that as a result an exchange may determine to
delist your securities. If the PCAOB has been or is currently unable to inspect your auditor, revise your disclosure to so state. In addition,
revise the disclosure in the heading and body of the risk factor on page 13 accordingly.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, we have added a section named &ldquo;<I>Cautionary Statement Regarding Holding Foreign Companies Accountable Act</I>&rdquo;
on page 10 under the prospectus summary of the Registration Statement. Our auditor, like other independent registered public accounting
firms operating in China, is not permitted to be subject to inspection by the PCAOB. We have revised the heading and body of the risk
factor on page 16 accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Risk Factors, page 8</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>9.</B></TD><TD STYLE="text-align: justify"><B>Revise your risk factor on page 9 to acknowledge that if the PRC government determines that the contractual
arrangements constituting part of your VIE structure do not comply with PRC regulations, or if these regulations change or are interpreted
differently in the future, your securities may decline in value or become worthless if you are unable to assert your contractual control
rights over the assets of your PRC subsidiaries that conduct all or substantially all of your operations.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, we have revised the risk factor on page 12 titled &ldquo;<I>If the PRC government deems that the VIE Agreements
do not comply with PRC regulatory restrictions on foreign investment in the relevant industries or other laws or regulations of the PRC,
or if these regulations or the interpretation of existing regulations change in the future, we could be subject to severe penalties or
be forced to relinquish our interests in those operations, which may therefore materially reduce the value of our ordinary shares or cause
them to become worthless</I>&rdquo; to acknowledge the risks mentioned above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>10.</B></TD><TD STYLE="text-align: justify"><B>Given the Chinese government&rsquo;s significant oversight and discretion over the conduct of your
business, please revise to separately highlight the risk that the Chinese government may intervene or influence your operations at any
time, which could result in a material change in your operations and/or the value of the securities being offered. Also, given recent
statements by the Chinese government indicating an intent to exert more oversight and control over offerings that are conducted overseas
and/or foreign investment in China-based issuers, acknowledge the risk that any such action could significantly limit or completely hinder
your ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or
be worthless.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, we have revised the risk factor on page 11 titled &ldquo;<I>Substantial uncertainties and restrictions with respect
to the political and economic policies of the PRC government and PRC laws and regulations could have a significant impact upon the business
that we may be able to conduct in the PRC and accordingly on the results of our operations and financial condition</I>&rdquo; to highlight
that &ldquo;Chinese government may intervene or influence our operations at any time, or may exert more control over offerings conducted
overseas and/or foreign investment in China-based issuers, which could result in a material change in our operations and/or the value
of the securities being offered. Any adverse changes in Chinese laws and regulations and the Chinese government&rsquo;s significant oversight
and discretion over the conduct of our business could significantly limit or completely hinder our ability to offer or continue to offer
securities to investors and cause the value of our securities to significantly decline or be worthless.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>11.</B></TD><TD STYLE="text-align: justify"><B>We note your current disclosure on pages 11-12. In light of recent events indicating greater oversight
by the Cyberspace Administration of China over data security, please revise your disclosure to explain how this oversight impacts your
business and your offering and to what extent you believe that you are compliant with the regulations or policies that have been issued
by the CAC to date.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>Response: </B>In response to the
Staff&rsquo;s comment, we have revised our disclosure on pages 14-15 to address how the CAC&rsquo;s oversight impacts our business and
our offering and to what extent we believe that we are compliant with the regulations or policies that have been issued by the CAC to
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should any questions arise
in connection with the filing or this response letter, please contact Elizabeth F. Chen, Esq. at Pryor Cashman LLP at 212-326-0199 and
Will Rao, Esq. at Pryor Cashman LLP at 212-326-0498.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Sincerely yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">China Jo-Jo Drugstores Holdings, Inc. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Lei Liu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Lei Liu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">cc:</FONT></TD>
    <TD STYLE="width: 95%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Elizabeth F. Chen, Esq.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Will Rao, Esq.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pryor Cashman LLP</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">5</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
